LGG Probiotic for Travelers' Diarrhea: What the Research Shows About Prevention (2026)

Travelers' diarrhea is the most common medical complaint of international travelers, affecting a substantial portion of people traveling from low-risk to high-risk destinations. The causes are mostly bacterial, the timing tends to cluster in the first week of travel, and the consequences can range from a ruined two-day window to a derailed trip. The question of whether a probiotic taken before and during travel can reduce the risk is older than most people realize, and the published evidence is mixed but informative.

This article walks through what the research actually shows about Lactobacillus rhamnosus GG (LGG) specifically for travelers' diarrhea prevention, where the evidence is strongest, where it is weakest, and how to think about whether it belongs in your travel routine.

What Travelers' Diarrhea Actually Is

Travelers' diarrhea is typically defined as three or more loose stools in 24 hours plus an associated symptom such as cramping, nausea, fever, or urgency, occurring in someone who has recently traveled from a low-risk region to a higher-risk one. Most cases are caused by bacterial pathogens. Enterotoxigenic Escherichia coli (ETEC) has historically been the most commonly identified cause in many regions, with enteroaggregative E. coli, Campylobacter, Shigella, and Salmonella also contributing. More recent culture-independent molecular surveillance suggests that EAEC and other E. coli pathotypes may be equally or more prevalent in some regions, and norovirus is the leading viral cause.

The illness is mostly self-limited and resolves within three to seven days, but it accounts for the largest share of disrupted travel days and is a frequent reason for unplanned antibiotic use. Prevention strategies have historically focused on food and water precautions, with chemoprophylaxis and probiotics as adjunctive options that have been studied with varying rigor.

Why LGG Was Studied for This Purpose

LGG was one of the first probiotic strains to be commercialized with documented clinical research and remains one of the most thoroughly studied probiotics in the world. It survives gastric acid passage reasonably well, adheres to intestinal epithelial cells, and has been associated with effects on mucin production, tight junction integrity, and competitive exclusion of pathogens. Each of these properties has a plausible link to reducing the establishment of an enteric pathogen during a brief travel exposure window.

The mechanistic case is straightforward: if a probiotic can occupy intestinal binding sites, modulate mucosal immune signaling, and reinforce the barrier between gut lumen and the host, it has a plausible role in reducing the success of a pathogen attempting to colonize during a high-exposure window.

The Key Trial: Hilton et al. 1997

The most frequently cited study on LGG for travelers' diarrhea is Hilton and colleagues, published in the Journal of Travel Medicine in 1997. This was a randomized, double-blind, placebo-controlled trial in 245 travelers from the United States visiting destinations including developing-country regions. Participants took either LGG or placebo daily, starting two days before departure and continuing through their trip.

The headline finding was a modest reduction in diarrhea risk in the LGG group compared with placebo, with an overall protection rate that varied by destination. Travelers to certain destinations showed a more meaningful reduction in incidence than travelers to others, which is consistent with the local pathogen mix mattering for which interventions work.

The honest reading of this trial is that LGG reduced travelers' diarrhea risk modestly in an aggregate analysis, with destination-dependent variation. It did not eliminate risk, and it was not a substitute for sensible food and water practices. The effect size was in the range that makes the intervention a reasonable adjunctive measure rather than a primary defense.

What Meta-Analyses Have Found

Several meta-analyses have examined probiotics in general for travelers' diarrhea prevention. McFarland's 2007 meta-analysis in Travel Medicine and Infectious Disease pooled probiotic trials for travelers' diarrhea and found a statistically significant overall reduction in incidence, with Saccharomyces boulardii and a mixture of Lactobacillus acidophilus and Bifidobacterium bifidum showing the most consistent signal in pooled subgroups. The LGG evidence in that analysis came largely from the underlying Hilton trial and earlier work by Oksanen and colleagues (Annals of Medicine, 1990), which studied LGG in Finnish travelers to Turkey.

A subsequent systematic review by Bae (2018) summarized trials across multiple strains and destinations and concluded that the overall quality of the evidence was moderate, the effect sizes were modest, and the strain specificity mattered. The conclusion in most reviews is that probiotics are a reasonable adjunct, not a replacement for behavioral prevention.

The clinical practice guideline picture has reflected this caution. The International Society of Travel Medicine 2017 expert panel guideline concluded that there was insufficient evidence to recommend probiotics for routine travelers' diarrhea prophylaxis, while acknowledging that selected travelers may reasonably choose to use them.

Why the Effect Size Is Modest

There are several reasons the effect of LGG on travelers' diarrhea, even when statistically detectable, is moderate rather than dramatic.

First, the pathogen mix at any given destination is variable. LGG is not a directly antibacterial agent against ETEC, and its mechanism is more about strengthening host defenses than killing specific pathogens. A high pathogen load from contaminated food or water can overwhelm marginal improvements in barrier function.

Second, the dose and duration matter. Most travelers' diarrhea trials used daily probiotic doses for the duration of travel. Insufficient dose or short pre-travel loading periods may produce smaller effects. The probiotic needs time to establish before exposure occurs.

Third, individual variation is large. The baseline gut microbiome, prior antibiotic use, and host immune status all influence how a probiotic interacts with travel-related pathogen exposure. Group-average effects in a trial do not capture the range of individual outcomes.

None of these caveats invalidate the use of LGG for travelers' diarrhea. They simply explain why the reported effects are moderate rather than transformative, and why behavioral prevention remains the foundation of any travel strategy.

How LGG Fits Alongside Other Travelers' Diarrhea Strategies

The mainstays of travelers' diarrhea prevention remain behavioral. Drinking only sealed bottled or boiled water, avoiding ice in higher-risk destinations, choosing freshly cooked hot food over buffet items that have been sitting, and being cautious with uncooked produce all reduce exposure. These behaviors have larger effects on diarrhea risk than any probiotic.

For travelers at higher risk, including those with significant medical comorbidities or those for whom even a short illness would derail an important trip, antibiotic chemoprophylaxis has been studied. Rifaximin in particular has shown efficacy for prevention in some studies, with the caveat that prophylactic antibiotic use has its own considerations around resistance and microbiome disruption. This is a conversation to have with a travel medicine clinician, not a self-prescribing decision.

LGG fits as an adjunct on top of behavioral prevention. It is not a substitute for hand hygiene, food and water caution, or appropriate vaccination. It is a low-risk supplement that may provide a modest additional layer of defense, and it has the secondary benefit of supporting general gut function during a period of dietary disruption, jet lag, and stress.

LGG for Recovery from Travel-Related Antibiotic Use

A second use case for LGG in the travel context is recovery, not prevention. If a traveler develops diarrhea and is prescribed an antibiotic, LGG has a separate body of evidence for reducing the risk of antibiotic-associated diarrhea. Goldenberg and colleagues' 2015 Cochrane review on probiotics for the prevention of pediatric antibiotic-associated diarrhea (and the related adult literature) found that probiotics reduced the incidence of antibiotic-associated diarrhea, with LGG and Saccharomyces boulardii among the better-studied strains.

The practical implication is that LGG taken alongside an antibiotic course during or after travel may reduce the additional gut disruption that antibiotics cause. Our LGG probiotic for antibiotic-associated diarrhea article covers this in more depth.

Dose, Timing, and Form for Travel

For travel use, the most defensible approach mirrors what has been studied: begin LGG two to five days before departure to give the strain time to establish, continue daily throughout the trip, and continue for at least a few days after return to support recovery from the dietary disruption of travel.

Wise Choice's LGG probiotic provides 30 billion CFU per capsule. The original travelers' diarrhea trials (Hilton 1997, Oksanen 1990) used roughly 2 billion CFU per day, so 30 billion CFU per capsule is well above what those specific TD trials evaluated. Higher daily doses of LGG have been used safely in other indications, including antibiotic-associated diarrhea trials and IBS studies. Once daily dosing is generally sufficient, with the capsule taken with food to buffer gastric acid exposure during transit through the stomach.

For travel logistics, room temperature stability matters. Many probiotic products require refrigeration, which is impractical for travel. The shelf-stable formulation is the more travel-friendly option, allowing the capsules to remain viable during transit and in destinations without reliable refrigeration.

Who Should Be Cautious

LGG has an extensive safety profile and is generally well tolerated. The exceptions are people who are severely immunocompromised, have central venous catheters, or have specific medical conditions in which any live microorganism intake requires medical supervision. Rare cases of bacteremia have been reported in vulnerable populations. These are clinical situations where probiotic use should be discussed with a physician rather than initiated independently.

For the majority of healthy travelers, LGG is a low-risk supplement with a long history of clinical use. Side effects, when reported, are typically mild and gastrointestinal in nature, such as transient bloating during the first few days of use.

The Bottom Line

LGG has been studied for travelers' diarrhea prevention since the early 1990s (Oksanen et al. 1990, Annals of Medicine; Hilton et al. 1997, Journal of Travel Medicine), and the evidence supports a modest reduction in diarrhea risk when taken before and during travel. The effect is not dramatic, it does not replace food and water precautions, and it is not a primary defense against high-risk pathogen exposures. It is a reasonable adjunctive measure for travelers who want an additional low-risk layer of support, and it has separate value for reducing antibiotic-associated diarrhea if antibiotics are needed during or after travel.

The most defensible use is: start LGG two to five days before departure, continue daily through the trip and for several days after return, maintain rigorous food and water practices throughout, and treat the probiotic as a small additional input rather than a primary intervention. For travelers heading to higher-risk destinations who have a history of travelers' diarrhea or who simply want to reduce the odds, LGG is a reasonable, well-studied, and low-risk choice to include in the travel kit.